As an example, Fernandez-Cuesta and colleagues [12] recently used a pipeline specifically designed to accurately detect sequence variants present at very low fractions in cfDNA from patients with small-cell lung cancer (SCLC), addressing TP53 mutations, which are known to occur in the majority of cases of SCLC [13]. The gene discussed is TP53; the disease is small cell lung carcinoma.